Mortality and morbidity after combined heart and liver transplantation in the failing Fontan: An updated dual center retrospective study

Clin Transplant. 2024 Apr;38(4):e15302. doi: 10.1111/ctr.15302.

Abstract

Introduction: As the adult Fontan population with Fontan associated liver disease continues to increase, more patients are being referred for transplantation, including combined heart and liver transplantation.

Methods: We report updated mortality and morbidity outcomes after combined heart and liver transplant in a retrospective cohort series of 40 patients (age 14 to 49 years) with Fontan circulation across two centers from 2006-2022.

Results: The 30-day, 1-year, 5-year and 10-year survival rate was 90%, 80%, 73% and 73% respectively. Sixty percent of patients met a composite comorbidity of needing either post-transplant mechanical circulatory support, renal replacement therapy or tracheostomy. Cardiopulmonary bypass time > 283 min (4.7 h) and meeting the composite comorbidity were associated with mortality by Kaplan Meier analysis.

Conclusion: Further study to mitigate early mortality and the above comorbidities as well as the high risk of bleeding and vasoplegia in this patient population is warranted.

Keywords: Fontan associated liver disease; cardiopulmonary bypass; combined heart and liver transplantation; mechanical circulatory support; single ventricle; vasoplegia.

MeSH terms

  • Adolescent
  • Adult
  • Heart Defects, Congenital* / surgery
  • Heart Transplantation*
  • Humans
  • Liver Diseases* / surgery
  • Liver Transplantation* / adverse effects
  • Middle Aged
  • Morbidity
  • Retrospective Studies
  • Young Adult